论文部分内容阅读
目的评价左旋卡尼汀治疗慢性充血性心力衰竭患者的疗效性和安全性。方法充血性心力衰竭患者52例,被随机分为治疗组(28例)和对照组(24例)。两组均给予常规抗心力衰竭治疗,治疗组加用左旋卡尼汀3·0g加入5%葡萄糖100ml静脉滴注,1次/d,疗程2周。于治疗前和疗程结束时测定心功能指标:左室射血分数(LVEF),心排血量(CO),左室短轴缩短率(FS),左室舒张末期内径(LVDd)。结果治疗组心功能明显好转,LVEF、CO、FS和LVDd较治疗前明显改善,与对照组比较,差异有统计学意义(P<0·05)。治疗组有1例患者出现乏力、心动过缓,但能耐受。结论左旋卡尼汀治疗慢性充血性心力衰竭是安全有效的。
Objective To evaluate the efficacy and safety of L-carnitine in patients with chronic congestive heart failure. Methods Fifty-two patients with congestive heart failure were randomly divided into treatment group (n = 28) and control group (n = 24). Two groups were given routine anti-heart failure treatment, the treatment group plus levocarnitine 3 · 0g 5% glucose 100ml intravenous infusion, 1 / d, treatment for 2 weeks. Before treatment and at the end of treatment, the cardiac function indexes were measured: LVEF, CO, FS, LVDd. Results The cardiac function of the treatment group improved obviously. The levels of LVEF, CO, FS and LVDd in the treatment group were significantly improved compared with those before treatment. The difference was statistically significant (P <0.05). One patient in the treatment group developed fatigue, bradycardia, and tolerated. Conclusion L-carnitine is safe and effective in the treatment of chronic congestive heart failure.